EHMT2 and breast carcinoma: The concurrent inhibition of G9a and class I histone deacetylases (HDACs) suppresses the gene signatures of CSCs, EMT, drug resistance and cell fate determination in breast cancer, resulting in growth suppression and the apoptosis of breast cancer cells [117].